Bupropion, sold under the brand name Wellbutrin, is not FDA-approved for ADHD, but some prescribers use it off-label for ADHD symptoms. Off-label means the drug is used for a condition its FDA label does not cover, so the choice rests on the prescriber's judgment and the research behind it. The main review of adult trials, a 2017 Cochrane review, found a possible benefit over placebo but rated the evidence as low quality.
This page walks through what off-label use means, what the trials found, the risks a prescriber should discuss, how age changes the picture, and a checklist for your appointment. It does not give doses. For the basics of ADHD itself, the NIMH ADHD overview is a useful starting point.
What does off-label use mean for bupropion and ADHD?
The Cochrane review describes bupropion as registered for depression and smoking cessation, and used off-label to treat ADHD. ADHD Advisor's treatment page, captured October 15, 2026, says that off-label ‘simply means that the FDA does not currently approve it for the specific condition.' That same page lists depression, seasonal affective disorder and nicotine dependence as its FDA-approved uses.
Off-label prescribing is a question about the label, not a verdict on the drug. It means the decision about whether to use bupropion, and how to monitor it, depends on your prescriber's judgment and on the studies below.
What did the research on bupropion for ADHD find?
The Cochrane review pooled six randomized trials with 438 adults. All of them used a long-acting form of bupropion for six to 10 weeks. It found low-quality evidence that ADHD symptom severity fell more on bupropion than on placebo, and that more people reached clinical improvement. Its reviewers say the findings indicate a possible benefit and that more research is needed.
| Study | Who was studied | What it found | What it cannot tell you |
|---|---|---|---|
| Cochrane review, 2017 | 438 adults in six randomized trials, five in the USA and one in Iran | Lower symptom severity than placebo; more clinical improvement; withdrawals for side effects similar to placebo | Low-quality evidence; small trials; little on long-term outcomes; response in people with a DSM-5 diagnosis not yet reported |
| Review, 1998 | Children and adults, reviewed together | Presents bupropion as a nonstimulant option, noting that not all patients respond to psychostimulants and some have significant side effects | An older review, not a new controlled trial |
| Open trial, 1998 | 13 nondepressed adolescent boys in a residential program, with ADHD, conduct disorder and substance use disorder; 5 weeks | Conners Hyperactivity Index fell from 75.5 to 65.4; clinician severity rating fell from 4.9 to 3.0 | No control group; the authors call the data preliminary and say a controlled trial is needed |
| Randomized trial, 2006 | 98 adults on methadone maintenance with adult ADHD; 12 weeks; 53% also met criteria for cocaine dependence or abuse | No clear advantage over placebo for bupropion or methylphenidate; 46% of the placebo group reported substantial improvement on one measure | A specialized group that differs from most adults with ADHD |
Read together, a few small trials point to a possible benefit, the largest review rates that evidence as low quality, and a 2006 trial in a specialized population found no clear advantage over placebo. The Cochrane review compared bupropion only with placebo. No head-to-head comparison with stimulants appears in it, so it cannot tell you how bupropion ranks against them. For how trials report side effects and where their limits lie, the Clinical Study Safety Data guide explains what to look for.
What risks should a prescriber discuss?
Risk is part of the decision, so bring these to your appointment. The side effects below come from ADHD Advisor's treatment page and from Thriveworks' ADHD article, both captured October 15, 2026.
| Risk | Where the sources list it | What to raise |
|---|---|---|
| Insomnia and sleep problems | ADHD Advisor; Thriveworks | Tell your prescriber about any change in sleep |
| Dry mouth, nausea, constipation, headache, dizziness | ADHD Advisor | Name the ones that bother you most |
| Anxiety | ADHD Advisor; Thriveworks (with Adderall) | Share any anxiety history before starting |
| Seizures (listed as dose-related) | ADHD Advisor | Share your seizure history |
| Mania; delusions, hallucinations and paranoia | ADHD Advisor | Share any bipolar history |
| High blood pressure | ADHD Advisor; Thriveworks (when combined with Adderall) | Ask about blood pressure checks |
| Suicidal thoughts or behaviors | ADHD Advisor, citing the FDA boxed warning for children, adolescents and young adults | Ask how you or your family will be monitored |
| Glaucoma; allergic reactions | ADHD Advisor | Share eye-pressure and allergy history |
| Vertigo, poor appetite, blurred vision, irritability, muscle tremors, sweating | Thriveworks | Report new symptoms rather than adjusting anything yourself |
Who should not take it?
ADHD Advisor's page lists situations where bupropion should not be used. These include a known allergy to its ingredients, a seizure disorder, certain eating disorders, kidney or liver disease, use of an MAOI, use of another bupropion product, stopping a benzodiazepine or heavy alcohol use, use of an antiseizure medication, and use of ritonavir, aripiprazole or tramadol. Your prescriber checks this list against your full history and the current FDA drug label.
Is a nonstimulant the same as risk-free?
No. Bupropion is not a stimulant, but that only answers one question. ADHD Advisor describes it as not a controlled substance, which is a scheduling fact and does not describe every risk. The suicidality warning and seizure risk listed above still apply.
Thriveworks says bupropion is ‘unlikely to make ADHD effects worse,' but also lists common side effects, and says a different medication may suit some people better with fewer side effects. A prescriber weighs those effects against the impairment you have now, the alternatives, and how closely you can be monitored. The Cochrane review found that people leaving trials because of side effects were about as common on bupropion as on placebo, but its confidence interval was wide (0.35 to 4.10), so the data cannot show how common side effects are in practice.
Does age change the picture?
Yes. The Cochrane review covers adults only. The only adolescent data here is the 1998 open trial in 13 boys, which had no control group. ADHD Advisor says its bupropion service works with adults aged 18 and older and that the drug ‘is not approved for pediatric use.' Its boxed-warning note covers children, adolescents and young adults. Off-label use in a child is therefore a separate conversation, and it needs a clinician who works with children. The CDC's clinical care guidance for children with ADHD is the place to start for that discussion.
Can bupropion be combined with an ADHD stimulant?
Thriveworks says a prescriber may use both if stimulants alone have not worked, or if depression occurs alongside ADHD. It also says the combination can increase some side effects, including high blood pressure, sensitivity to alcohol and anxiety, and should happen under close medical supervision. ADHD Advisor says bupropion can be added to a stimulant when depression and ADHD occur together, or when the stimulant is not reducing symptoms enough on its own. For interactions in more detail, read our Stimulant Medication Interactions guide.
What if I also have anxiety, depression or bipolar disorder?
The Cochrane review notes that ADHD often comes with other psychiatric conditions, and four of its six trials excluded people with a psychiatric comorbidity. The trial evidence therefore says least about people with several conditions at once. Thriveworks says a prescriber may consider bupropion when depression is present with ADHD. ADHD Advisor lists anxiety among common side effects of Wellbutrin. Thriveworks mentions anxiety only as a possible effect when Wellbutrin is combined with Adderall.
The evidence here does not provide results specifically for people with bipolar disorder. ADHD Advisor lists mania among its more serious side effects, so share any bipolar history before a prescription is written. If you are not sure whether attention trouble is ADHD or anxiety, our Is Brain Fog ADHD or Anxiety? guide covers signs, triggers and diagnosis.
How long until you would know it is working?
Thriveworks says some people notice benefits within 2 to 4 weeks and some within 3 to 7 days. Those are provider statements, not trial results. The Cochrane trials ran six to 10 weeks, and the review says long-term outcomes are poorly known. The trials measured ADHD symptom rating scales and clinician ratings of improvement. Ask your prescriber which measures they will track, when they will check, and what they will do if there is no change. A quick change reported online is not proof that the drug is working for you.
Does bupropion make ADHD worse or cause tiredness?
Thriveworks says bupropion is unlikely to make ADHD worse, but it may cause side effects such as sleep problems, headaches, irritability and sweating. ADHD Advisor lists insomnia and dizziness. Neither seller page names tiredness as a side effect. If you feel unusually tired, tell your prescriber rather than changing anything yourself.
Do I need ADHD medication at all?
The sources here cannot tell you whether you need medication. That depends on your symptoms, how much they affect daily life, and a clinical assessment. Before that appointment, the What Unmedicated ADHD Feels Like: Signs & Assessment page can help you describe what you notice. Non-drug approaches are part of the picture too, and our ADHD management beyond medication guide covers lifestyle, diet and cognitive training.
How does bupropion compare with other ADHD options?
The table below is for your clinician conversation. The sources cited here do not compare these options head to head, so ask your prescriber how each fits your history.
| Option | Type, as the sources describe it | What the sources say |
|---|---|---|
| Bupropion (Wellbutrin) | Nonstimulant; norepinephrine-dopamine reuptake inhibitor | Used off-label for ADHD; low-quality trial evidence against placebo |
| Stimulants (Adderall, Vyvanse, Concerta, Ritalin) | Stimulant | Described as the mainstay of treatment; Thriveworks says 30% to 50% of people with ADHD get limited benefit from stimulants |
| Atomoxetine (Strattera) | Nonstimulant; norepinephrine reuptake inhibitor | Listed as a nonstimulant alternative by both seller pages |
| Viloxazine | Nonstimulant; norepinephrine reuptake inhibitor | Described by ADHD Advisor as an option outside stimulants |
| Guanfacine (Intuniv) and clonidine (Kapvay) | Nonstimulant; alpha-2 agonists | Listed as nonstimulant alternatives by both seller pages |
Thriveworks says a prescriber may consider bupropion when a stimulant carries a misuse concern. That is a clinical judgment, not a trial result.
A checklist for your appointment
- Ask whether bupropion would be off-label for you, and which FDA-approved uses the label lists.
- Ask which trial evidence applies to someone your age and with your other conditions.
- Share your seizure history, any eating disorder, kidney or liver disease, alcohol use, depression, anxiety, bipolar history and blood pressure.
- List every medicine and supplement you take, including stimulants and over-the-counter products.
- Ask about the suicidality boxed warning and how you will be monitored.
- Ask which symptom measures will be tracked and when you will be reassessed.
- Ask what happens if side effects appear or your symptoms do not change.
- Ask whether an assessment or non-drug support should come before medication.
What the evidence cannot tell us yet
- Long-term outcomes. The Cochrane review says little is known about them.
- Response in people with a DSM-5 diagnosis, which the review says has not yet been reported.
- Controlled results in adolescents. The only adolescent data here is one open trial of 13 boys.
- Results in people with bipolar disorder or several conditions at once.
- How bupropion compares with stimulants, since no head-to-head trial is cited.
- Which people benefit most. The review says the target population still needs clarifying.
This is information, not legal advice. As of October 15, 2026, the FDA drug label is the official source for bupropion's approved uses; this article did not check that label. ADHD Advisor, a seller, describes bupropion as approved for depression, seasonal affective disorder and nicotine dependence, and not for ADHD. Check the current FDA drug label and ask your prescriber about it.
By the Global MH Summit Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.